Janux Therapeutics (JANX) Net Margin (2021 - 2025)
Historic Net Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 243.13%.
- Janux Therapeutics' Net Margin rose 61484400.0% to 243.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1018.95%, marking a year-over-year decrease of 5550400.0%. This contributed to the annual value of 651.62% for FY2024, which is 695600.0% up from last year.
- Janux Therapeutics' Net Margin amounted to 243.13% in Q3 2025, which was up 61484400.0% from 6391.57% recorded in Q3 2024.
- Janux Therapeutics' 5-year Net Margin high stood at 66.98% for Q2 2024, and its period low was 6391.57% during Q3 2024.
- For the 5-year period, Janux Therapeutics' Net Margin averaged around 1126.13%, with its median value being 837.06% (2021).
- Per our database at Business Quant, Janux Therapeutics' Net Margin plummeted by -59319800bps in 2024 and then surged by 61484400bps in 2025.
- Quarter analysis of 5 years shows Janux Therapeutics' Net Margin stood at 830.2% in 2021, then surged by 32bps to 564.67% in 2022, then rose by 15bps to 477.77% in 2023, then plummeted by -1238bps to 6391.57% in 2024, then skyrocketed by 96bps to 243.13% in 2025.
- Its Net Margin stands at 243.13% for Q3 2025, versus 6391.57% for Q3 2024 and 66.98% for Q2 2024.